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Background: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Children with JIA
are at risk of intraocular inflammation (uveitis). In the initial stages of mild-moderate inflammation uveitis is asymptomatic.
Most children with mild-moderate uveitis are managed on topical steroid drops with or without systemic methotrexate
(MTX). When children with moderate-severe uveitis are refractory to MTX, monoclonal anti-tumour necrosis factor agents
have been trialled, interim analysis data showed positive results. However, several children with severe recalcitrant disease
or non-responsive to anti-tumour necrosis factor agents remain and are at greater risk of significant ocular complications
and visual loss. Further evidence of alternative therapies is needed with evidence of a potential role of anti-interleukin-6
agents in the management of severe refractory uveitis.
Methods: The trial will be conducted following a two-stage Simon design. The trial will register at least 22 patients aged
2 to 18 years with active JIA-associated uveitis, who have taken MTX for at least 12 weeks and have failed an anti-TNF
agent. It will take place in 7 centres across the UK. All participants will be treated for 6 months, with follow up of 9 months
from registration. Participants will receive a stable dose of MTX and those weighing ≥30 kg will be dosed with 162 mg of
Tocilizumab every 2 weeks and participants weighing < 30 kg dosed with 162 mg of Tocilizumab every 3 weeks. Primary
outcome is treatment response at 12 weeks. Adverse events will be collected up to 30 calendar days following
treatment cessation.
Discussion: This is a novel adaptive design study of subcutaneous IL-6 inhibition in anti-TNF refractory JIA associated
uveitis which will be able to determine if further research should be conducted. This is the first trial to look
at ophthalmology outcomes in the efficacy of Tocilizumab in uveitis.
This is the first paediatric clinical trial to assess the clinical effectiveness and safety of tocilizumab with MTX in
JIA associated uveitis.
Trials registration: The Trial is registered on the ISRCTN registry (ISRCTN95363507) on the 10/06/2015 and EU
Clinical Trials Register on the 03/07/2015 (EudraCT Number: 2015–001323-23).
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Juvenile idiopathic arthritis (JIA) is the name for a type of
arthritis that primarily affects young people and whose
cause is unknown. Although ‘arthritis’ refers to inflamma-
tion of the joints, in JIA the inflammation may also affect
the eyes and other internal organs. Approximately 1 in
1000 children in the UK develops JIA per annum.
Although both genders are affected, JIA is most common
in girls. JIA is the most common rheumatic disease in
children. Children with JIA also are at risk of inflamma-
tion of the uvea in the eye (uveitis). 80% of all paediatric
uveitis is secondary to JIA [1, 2]. The major risk factors
for development of uveitis in JIA are oligoarticular pattern
of arthritis, early onset of arthritis, and antinuclear anti-
body positivity [3]. In the initial stages of mild to moderate
inflammation the uveitis is entirely asymptomatic.
Most children with mild to moderate uveitis are
managed on topical steroid drops and systemic metho-
trexate (MTX) as an immunosuppressive agent [4, 5]. As
a significant proportion of children with moderate-
severe uveitis are refractory to MTX [6–8], biologics in
the form of monoclonal anti-TNF agents have been
tried. The anti-TNF agents are effective only in 30–60%
of the patients based on several retrospective case series
[9]. When children with moderate-severe uveitis are
refractory to MTX, monoclonal anti-TNF agents have
been trialled [10] the results show that adalimumab in
combination with methotrexate was effective at treating
JIA-associated uveitis [11]. Unfortunately, anti-tumour
necrosis factor (anti-TNF) therapy is not the panacea ei-
ther for JIA alone, or JIA-associated uveitis. We know
that the uveitis in some patients may still flare despite
anti-TNF therapy. These children have severe recalci-
trant disease that is therefore at greater risk of causing
significant ocular complications and blindness.
Interleukin 6 (IL-6), glycoprotein 130, and IL-6 receptor
levels are all elevated in uveitis in many studies of sam-
pling of ocular fluids/tissues [12]. The cause of chronic
disease remains unknown but auto-inflammation driving
a dysregulated innate immunity will encompass an IL-6
mediated inflammatory response, particularly from mono-
nuclear cell populations and is a consistent feature of
animal models and human data to date [13]. As such, IL-6
is a suitable inflammatory pathway to therapeutically
target. Not surprisingly, there are anecdotal reports of suc-
cess of using anti-IL-6 therapy in the form of tocilizumab,
in refractory uveitis [14–16].
Rationale
In view of the failure of patients with refractory JIA-
associated uveitis to either respond, or subsequently flare
on anti-TNF therapy, and the strong evidence base for
the rationale for targeting IL-6 in the disease pathogen-
esis, a phase II trial of the potential efficacy, safety andtolerability of anti-IL-6 therapy is being undertaken to
decide whether further research is justified. Previous
studies investigating the effect of Tocilizumab in paedi-
atric arthritis have excluded patients with uveitis. How-
ever, data available for Tocilizumab used in treating
uveitis in adults indicates its potential role for refractory
disease [17]. A systematic search of existing data has
shown limited case reports [18].
Tocilizumab (trade name RoActemra) is a biological
therapy blocking the action of IL-6. In arthritis, high
concentrations of IL-6 are associated with tiredness,
anaemia, and inflammation and damage to bones,
cartilage and tissue. Tocilizumab reduces these effects.
Previous clinical trials of Tocilizumab in children with
systemic-onset JIA have shown that children respond
dramatically to treatment in a short time span [19].
Tocilizumab obtained National Institute for Health and
Care Excellence approval for this indication and became
the first drug to be licenced for the use of JIA in fifty
years. The trial in polyarticular forms of JIA shows a
good effect [20]. However these clinical trials for
Tocilizumab state that a diagnosis of uveitis is part of
the exclusion criteria and therefore no indication of
efficacy in uveitis can be determined.
Tocilizumab is now the first choice biologic in children
with systemic onset JIA and an important agent in the
management of refractory polyarticular JIA. An ongoing
Phase 1b, open-label, multicenter study to investigate the
pharmacokinetics, and safety of Tocilizumab following
subcutaneous administration to patient with polyarticular-
course juvenile idiopathic arthritis is currently underway
across 13 countries worldwide [21].
Potential risks and benefits
However, due care must be taken in determining the
potential benefits of Tocilizumab therapy against the
potential associated risks, and as such, the risk / benefit
assessment of this intervention and safety is a key
secondary outcome measure of the trial.
The most commonly reported Adverse Drug Reactions
(ADRs) (occurring in ≥5% of patients treated with
Tocilizumab monotherapy or in combination with
disease-modifying anti-rheumatic drugs) were upper
respiratory tract infections, nasopharyngitis, headache,
hypertension and increased alanine aminotransferase
test (ALT). The most serious ADRs were serious infec-
tions, complications of diverticulitis, and hypersensitivity
reactions [19, 20].
Less likely in a paediatric population, rheumatoid
arthritis patients have an increased risk of cardiovascular
disorders such as hypertension or hyperlipemia. There
are no known evidence that Tocilizumab treatment
effects demyelinating disorders in a paediatric popula-
tion. There are risks of local site reactions, including
Fig. 1 Schematic of Study Design. *Registration should take place
no later than 2 weeks after the beginning of screening
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sema among others.
Of note, Tocilizumab has been shown to reduce the
rate of progression of joint damage as measured by
X-ray and to improve physical function when given in
combination with methotrexate [20]. Tocilizumab treat-
ment has been shown in a randomized clinical trial of
polyarticular-course JIA, as well as systemic-onset JIA,
as demonstrating significant improvement, maintained
over time, of signs and symptoms and has a safety
profile consistent with that for adults with RA [20].
In view of these data, we aimed to develop the proto-
col and deliver the first paediatric clinical trial that will
assess the clinical effectiveness and safety of tocilizumab
in combination with MTX for the treatment of anti-
tumour necrosis factor refractory JIA-associated uveitis.
The protocol for this trial is presented here.
Methods
Trial design
APTITUDE is a single arm Phase II trial that will be
conducted following a two-stage Simon design [20].
Figure 1 outlines the schematic of trial design and
patient journey. All participants will be treated for
6 months, with follow-up after 3 months of treatment
cessation (continuing on MTX throughout). Recruitment
started on 3rd December 2015.
All participants will complete trial assessments as
shown in Table 1. Further details are available on the
trial’s website [22].
Study population
Children aged between 2 and less than 18 are eligible for
the trial and at screening must have active uveitis de-
fined as “2” readings of cellular infiltrate in anterior
chamber of Standardisation of the Uveitis Nomenclature
(SUN) criteria [23] grade ≥ 1+ or more during the
preceding 6 weeks. Participants must have failed an anti-
TNF agent and have been on at least one anti-TNF agent
regardless of dose for at least 12 weeks at any time
previously and must have been on MTX for at least
12 weeks (stable dose for 4 weeks prior to screening)
and failed. Participants of reproductive potential (males
and females), must use a reliable means of contraception
throughout their trial participation and post pubertal
females must have a negative serum pregnancy test
within 14 days prior to registration. Exclusion criteria
are summarised in Table 2.
Selection of centres
Criteria for the selection of centres will be determined
by the Trial Management Group based also on track
record of the centre recruitment to previous trials,
including trial of anti-TNF in JIA-associated uveitis [10].Initiation of centres will be undertaken in compliance
with the Clinical Trial Research Centre (CTRC) Stand-
ard Operating Procedures. Centres fulfilling the criteria
will be selected to be recruitment centres for the APTI-
TUDE trial and will be opened to recruitment upon suc-
cessful completion of all global and study-specific
conditions and once all necessary documents have been
returned to CTRC.Interventions
Patients will receive Tocilizumab dosed according to
body weight, with patients weighing ≥30 kg dosed
with 162 mg of Tocilizumab every 2 weeks and pa-
tients weighing < 30 kg dosed with 162 mg of Toci-
lizumab every 3 weeks. Trial intervention should be
given up to and including week 24. Patients weighing
< 30 kg will be given a maximum of 9 injections and
patients weighing ≥30 kg will be given a maximum of
13 injections.
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Table 2 Exclusion Criteria
Exclusion Criteria
Uveitis without a diagnosis of JIA fulfilling International League if
Associations for Rheumatology diagnostic criteria for JIA
(all subgroups that have uveitis).
Currently on Tocilizumab or has previously received Tocilizumab.
Previous registration into the APTITUDE trial. Participation in another clinical trial of investigational medicinal
product within the last 4 weeks or 5 serum half-lives
(whichever is longer) prior to registration.
More than 6 topical steroid eye drops per day per eye at time
of registration (dose must be stable for 1 week prior to registration).
For participants on Prednisone or Prednisone equivalent, change
of dose within 4 weeks prior to registration.
Participants on prednisone or prednisone equivalent with
a dose > 0.2 mg/kg per day.
No intraocular injection of disease modification agents including
steroids and anti-Vascular endothelial growth factor within
4 weeks prior to registration.
No intraocular surgery for previous 12 weeks prior to registration
or expected/panned for duration of study.
Lack of recovery from recent surgery or surgery within
6 weeks at the time of registration.
Intra-ocular pressure≥ 25 mmHg at time of registration. Participants requiring systemic therapy with oral anti-glaucoma
medication.
No disease modifying immunosuppressive drugs, other than
MTX in the 4 weeks prior to registration
History of active tuberculosis of less than 24 weeks treatment.
Latent tuberculosis not successfully treated for at least
4 weeks prior to registration (a test for latent tuberculosis infection
must be performed within 12 weeks prior to registration).
Auto-immune, rheumatic disease or overlap syndrome other
than JIA.
Females who are pregnant, lactating, or intending to become
pregnant during trial.
Known human immunodeficiency virus infection or other condition
characterized by a compromised immune system.
Any history of alcohol or drug abuse within 24 weeks prior to
registration.
Any active acute, sub-acute, chronic, or recurrent bacterial, viral,
systemic fungal, infection or any major episode of infection
requiring hospitalisation or treatment with IV antibiotics within
4 weeks of registration or treatment with oral antibiotics within
2 weeks of registration.
History of reactivation or new onset of a systemic infection such as
herpes zoster or Epstein−Barr virus within 8 weeks prior to registration.
Hepatitis B surface antigen or hepatitis C antibody positivity
or chronic viral or autoimmune hepatitis.
History of concurrent serious gastrointestinal disorders. Evidence of current serious uncontrolled concomitant cardiovascular
(including hyperlipidaemia), nervous system, pulmonary
(including obstructive pulmonary disease), renal and hepatic disease.
History of or current cancer or lymphoma. Persistently poorly controlled severe hypertension
(>95th percentile for height / age).
Uncontrolled diabetes mellitus. History of severe allergic or anaphylactic reactions to human,
humanized or murine monoclonal antibodies.
No live attenuated vaccines (including seasonal nasal flu vaccine,
varicella vaccine for shingles or chickenpox, measles, mumps and
rubella (MMR) or MMR varicella, oral polio vaccine and vaccines
for yellow fever, measles, mumps or rubella) 4 weeks prior to
registration, throughout the duration of the trial and for 8 weeks
following the last dose of study drug.
Previous treatment with any cell-depleting therapies, including
investigational agents or approved therapies.
Treatment with intravenous gamma globulin or plasmapheresis
within 24 weeks of registration
Any previous treatment with alkylating agents such as chlorambucil,
or with total lymphoid irradiation
Any significant medical or surgical condition that would risk the
participant’s safety or their ability to complete the trial
Any joint injections within 4 weeks prior to registration
Any psychological condition that in the opinion of the principal
investigator would interfere with safe completion of the trial
Demonstrations of clinically significant deviations from the
following laboratory parameters:
Serum creatinine > 1.5 × the upper limit of normal (ULN) for
age and sex
Aspartate Aminotransferase Test or ALT > 1.5 × the ULN for age
and sex
Total bilirubin > 1.3 mg/dL (> 23 μmol/L)
Platelet count < 150 × 103/μL (< 150,000/mm3) (< 150 × 109/L)
Haemoglobin < 7.0 g/dL (< 4.3 mmol/L)
White blood cell (WBC) count < 4000/mm3 (< 4.0 × 109/L)
Neutrophil count < 2000/mm3 (< 2.0 × 109/L)
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Participants who miss two consecutive doses or three doses
in total of Tocilizumab injection should cease trial treat-
ment and will be recorded as a withdrawal from treatment.
Concomitant therapy
A complete list of concomitant therapies that are
allowed during the course of the trial and those that are
not permitted can be found below.
The following medications are permitted:
 Low dose of steroids (≤0.2 mg/kg/day of prednisone
or prednisolone equivalent medication orally) are
permitted during the active phase of the trial.
 Topical steroid eye drops with maximum of 6
drops/ day at registration
 Failure to reduce eye drops to 2 drops/ day by or at
the 12 week visit will be considered a treatment
failure and the participant should cease trial
treatment.
 After 12 weeks topical treatment must be kept at
twice per day.
 Intraocular pressure medication apart from systemic
treatment with acetazolamide
 Maxidex, Predforte or equivalent – preparation to
be stipulated at screening and to remain unchanged
for individual throughout treatment-phase of trial
 Intra-articular joint injections
The following medications are not permitted:
 Intra-ocular or peri-ocular corticosteroid injection
 The introduction of oral steroids, or increase in oral
steroids, is not permitted at any time during the trial.
 Intravenous methylprednisolone at any time
 Other biologic therapies, including: etanercept,
infliximab, golimumab; rituximab, abatacept,
anakinra.
 Cyclosporine, mycophenolate mofetil, azathioprine,
lefunamide, sulfasalazine, hydroxychloroquine, any
other disease modifying, anti-rheumatic drug
 Systemic treatment with acetazolamide
Registration
Registration will be undertaken by delegated individuals
at trial sites. Participants will be registered using a se-
cure (24-h) web based registration programme.
Assessments and procedures
As described previously [10], after obtaining written
consent (and assent where appropriate) from the partici-
pant, parent or legal guardian, a medical/ophthalmic his-
tory will be taken and recorded on the appropriate casereport form (CRF) with particular emphasis on other
disorders of relevance and allergies.
Separate sections on the CRF will be provided to rec-
ord the JIA and uveitis specific medical/ophthalmic his-
tory and the participant’s other medical/surgical history.
Medication (prescription, over-the-counter, and herbal
supplements) use over the 4 weeks prior to the screen-
ing visit will also be recorded. Physical examination,
measures of disease activity and complications, medica-
tion history, surgical history and laboratory tests (haem-
atological and biochemical analysis and urinalysis) will
be performed at the screening visit and will be repeated
at each subsequent trial visit (see Table 1).
The visits are calculated from the date of the first dose
of investigational medicinal product (IMP). With regards
to treatment timelines, 1 month’s treatment is defined as
4 weeks; after commencing treatment the dates of each
subsequent visit should be made at four weekly intervals
from the date of the first dose of IMP. A window of
±7 days is allowed for these monthly visits, however for
determining treatment response there should be an
interval of at least 3 weeks between assessments. This
means that if a patient attends a visit late (within the +
7 days window) then their next visit must not be early.
The next visit must either be on the date as scheduled
applying the 4 weekly intervals from first dose of IMP,
or may be in the + 7 day period.
Primary endpoint
The primary endpoint is response after 12 weeks of
treatment.
Response to treatment is defined as per SUN criteria
[23] as a 2 step decrease in the level of inflammation
(anterior chamber cells) or decrease to zero between
baseline (prior to trial treatment initiation) and 12 weeks
of treatment.
Secondary endpoints
A complete list of secondary endpoints can be found
below.
1) Safety, tolerability and compliance
a) Adverse events, serious adverse events and adverse
events of special interest
b) Laboratory parameters (haematological and
biochemical analysis and urinalysis)
c) Participant diaries and dosing records will determine
tolerability and compliance throughout the trial
treatment period
2) Use of corticosteroids over duration of study period
and throughout follow up, including:
a. Total oral corticosteroid dose
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dose from entry dose
c. Topical corticosteroid use (frequency) compared to
usage at registration.
3) Optic and Ocular
a. Visual acuity measured by age-appropriate
logarithm of the minimum angle of resolution
assessment
b. Number of participants with resolution of associated
optic nerve or macular oedema (as assessed by slit
lamp bio microscopy or optical coherence
tomography).
c. Number of participants who are able to reduce
topical or systemic agents for ocular hypertension.
d. Number of participants with disease control (defined
as zero cells, with topical treatment at 12 weeks
treatment visit and 24 weeks treatment visit.)
e. Number of participants entering disease remission
(defined as zero cells, without topical treatment at
12 and 24 weeks treatment visit)
f. Duration of sustaining inactive disease (zero cells,
with or without topical treatment.)
g. Failure to reduce eye drops to 2 drops/day by or at
the 12 weeks visit
4) Quality of Life assessment (Childhood Health
Questionnaire [24], (Childhood Health Assessment
Questionnaire [25]).
5) American College of Rheumatology (ACR) Pedi
core set criteria [26]: at ACR30, ACR50, ACR70, ACR90
and ACR100 levels.
6) Number of participants requiring change in biologic
/ Disease-modifying anti-rheumatic drugs therapy due to
disease flare of their arthritis or failure to respond to
treatment for their arthritis.
7) Number of participants undergoing flare of arthritis
[27], in remissions on and off medication of their Juven-
ile Idiopathic Arthritis [28] and with minimum disease
activity [29].
8) Participants score of the Juvenile Arthritis Disease
Activity Score (JADAS) [30]. The JADAS comprises four
components: physician global assessment of disease ac-
tivity parent/patient global assessment of well-being ac-
tive joint count, in 27, 71 or 10 joints; and (27)
erythrocyte sedimentation rate.
Sample size
The trial will be conducted following a two-stage Simon
design [31]. The null hypothesis (response = 20%)
reflects a response rate of no clinical benefit while the
alternative hypothesis (response = 50%) reflects a desired
response. The interim and final sample sizes and thecritical values for abandoning Tocilizumab at each stage
have been chosen to achieve the following properties. If
the true success probability is 0.2 then we will recom-
mend further study of Tocilizumab with probability less
than 0.05 (falsely pursuing a non-promising therapy). If
the true success probability is 0.5 then we will recommend
further study of Tocilizumab with probability greater than
0.9 (correctly pursuing a promising therapy).
After 10 participants have completed their 3 month
follow up there will be an interim analysis. If there are 8
or more non-treatment responses then the trial will stop
with the conclusion that the study of Tocilizumab
should be abandoned. If there are fewer than 8 non-
treatment responses then the study will continue until a
further 12 participants have received treatment, giving a
total sample size of 22. If amongst these 22 participants
there are 15 or more non-treatment responses then it
will be concluded that the further study of Tocilizumab
should be abandoned. If further study of the drug is not
abandoned at either the interim of the final analysis,
then a recommendation to conduct a comparative, ran-
domised phase III trial will be made.
Formal interim analyses of the accumulating data will
be performed at regular intervals (as described above)
for review by an Independent Data Monitoring and
Safety Committee (IDSMC). The IDSMC will make
recommendations to the Trial Steering Committee as to
the continuation of the trial.
Analysis plan
The analysis will be carried out according to the pre-
defined statistical analysis plan, which can be seen in
Additional file 1. If consent to treatment is withdrawn
but the participant agrees to remain in the study for
follow-up, the participant will be followed until comple-
tion. If the participant decides to withdraw consent com-
pletely, however, the reasons for withdrawal of consent
will be recorded (if possible) and reported.
The primary outcome is ‘response to treatment’ and in
the final analysis, point estimates and confidence inter-
vals will be computed using the method described by
Jovic and Whitehead [32].
Study organisation and funding
APTITUDE is co-ordinated from the CTRC at the
University of Liverpool and is sponsored by University
Hospitals Bristol NHS Foundation Trust, and has been
developed by the UK’s Experimental Arthritis Treatment
Centre for Children [33]. It is an independent trial funded
by Arthritis Research UK. The trial has a Trial Steering
committee (which compromises of independent members
as well as the Chief Investigators, namely AR and MWB)
and an Independent Data and Safety Monitoring Commit-
tee. The IMP is provided by Roche Products Limited.
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This trial is a novel adaptive design study of subcutane-
ous IL-6 inhibition in anti-TNF refractory JIA associated
uveitis which will be able to determine if further
research into the use of this intervention for the treat-
ment of anti-TNF refractory JIA-associated uveitis
should be conducted. This is the first trial to look at
ophthalmology outcomes in regards to the efficacy of
Tocilizumab in uveitis. This is the first paediatric clinical
trial that will assess the clinical effectiveness and safety
of tocilizumab in combination with MTX for the treat-
ment of anti-tumour necrosis factor refractory JIA-
associated uveitis. The results of this study will help de-
cide if further investigation into the effectiveness of toci-
lizumab is warranted in future clinical trials.
Trial status
This summary is based on version 4.0 of the study
protocol, dated 31st May 2017.
At the time of submission this trial is open in 7 Hos-
pital sites and has recruited 19 participants.
Additional file
Additional file 1: Statistical analysis plan (PDF 607 kb)
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